Detected ·
Altay Therapeutics
$37M—
Altay Therapeutics announced the close of a $37M Series A financing to advance DX5057, the first oral DUX4 inhibitor, into clinical trials for FSHD, with Phase 1 expected in Q1 2027.
- Website
- —
- linkedin.com/company/69914567
- Amount
- $37 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-10-15 08:04:38 UTC
- Signal ID
- dc631ccd-8248-4e7d-8f91-646b328ffcd9
As the API returns it
{
"id": "dc631ccd-8248-4e7d-8f91-646b328ffcd9",
"created_at": "2026-10-15T08:04:38.783114Z",
"company_name": "Altay Therapeutics",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/69914567",
"event_type": "funding",
"funding_amount": 37000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Altay Therapeutics announced the close of a $37M Series A financing to advance DX5057, the first oral DUX4 inhibitor, into clinical trials for FSHD, with Phase 1 expected in Q1 2027.*"
}